- CU-CPT-9a
-
- $34.00 / 1mg
-
2024-11-19
- CAS:2165340-32-7
- Min. Order:
- Purity: 99.01%
- Supply Ability: 10g
|
| | 4-(7-methoxyquinolin-4-yl)-2-methylphenol Basic information |
| Product Name: | 4-(7-methoxyquinolin-4-yl)-2-methylphenol | | Synonyms: | 4-(7-methoxyquinolin-4-yl)-2-methylphenol;CU-CPT-9B, CPD2004;CU-CPT-9b;2-Methyl-4-(7-methoxy-4-quinolinyl)phenol;cas 2165340-32-7;CU-CPT-9B;CAS 2165340-32-7 ;TLR8 INHIBITOR;Phenol, 4-(7-methoxy-4-quinolinyl)-2-methyl-;CU-CPT9a >=98% (HPLC) | | CAS: | 2165340-32-7 | | MF: | C17H15NO2 | | MW: | 265.31 | | EINECS: | | | Product Categories: | | | Mol File: | 2165340-32-7.mol |  |
| | 4-(7-methoxyquinolin-4-yl)-2-methylphenol Chemical Properties |
| Boiling point | 429.7±45.0 °C(Predicted) | | density | 1.201±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMF: 30 mg/ml; DMF:PBS (pH 7.2) (1:9): 0.1 mg/ml; DMSO: 10 mg/ml; Ethanol: 5 mg/ml | | form | A crystalline solid | | pka | 8.47±0.20(Predicted) | | color | Light yellow to yellow |
| | 4-(7-methoxyquinolin-4-yl)-2-methylphenol Usage And Synthesis |
| Uses | CU-CPT9a is a potent TLR8 inhibitor (IC50 = 0.5 nM and Kd = 21 nM). Stabilizes the TLR8 dimer in its resting state, preventing activation. Suppresses TLR8-mediated proinflammatory signaling in various cell lines and human primary cells. | | Biological Activity | CU-CPT9a is a potent and selective inhibitor of Toll-like receptor 8 (TLR8). It binds to TLR8 at a site different from current small-molecule TLR7/8 agonists, stabilizing the TLR8 dimer in its resting state, thus preventing TLR8 activation It exhibited an IC50 value of 0.5 nM and blocked TLR8 activation induced by either resiquimod (R848) or ssRNA without affecting the closely related TLR7 or cells expressing other TLRs. CU-CPT9a also suppressed TNF-α levels in a dose-dependent manner in cells from patients with rheumatoid arthritis. | | storage | Store at -20°C |
| | 4-(7-methoxyquinolin-4-yl)-2-methylphenol Preparation Products And Raw materials |
|